✦ LIBER ✦

648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS

✍ Scribed by Miller, Kurt; Fizazi, Karim; Smith, Matthew; Moroto, Jose Pablo; Klotz, Laurence; Brown, Janet; Tammela, Teuvo LJ; Shore, Neal; Ke, Chunlei; Chung, Karen; Goessl, Carsten

Book ID: 122438230
Publisher: Lippincott Williams and Wilkins
Year: 2011
Tongue: English
Weight: 110 KB
Volume: 185
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2011.02.1550

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P347 Benefit of denosumab therapy in pat

P347 Benefit of denosumab therapy in patients with bone metastases from breast cancer: A number-needed-to-treat (NNT) analysis

✍ M. Martin; G. Steger; R. von Moos; A. Stopeck; R. de Boer; H. Bourgeois; K. Inou 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 35 KB

176 NUMBER NEEDED TO TREAT AND RISK BENE

176 NUMBER NEEDED TO TREAT AND RISK BENEFIT ANALYSIS OF DENOSUMAB VERSUS ZOLEDRONIC ACID IN THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER PATIENTS WITH BONE METASTASES

✍ Xie, Jipan; Diener, Melissa; Wu, Eric; Sorg, Rachael; Yu, Andrew; Namjoshi, Madh 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 47 KB

1091 PAIN OUTCOMES IN PATIENTS WITH BONE

1091 PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID

✍ Brown, J.E.; Cleeland, C.S.; Fallowfield, L.J.; Patrick, D.L.; Fizazi, K.; Smith 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 205 KB

3602 POSTER The Number Needed to Treat (

3602 POSTER The Number Needed to Treat (NNT) as a Measure of Incremental Drug Benefit: Denosumab Vs. Zoledronic Acid for the Prevention of Skeletal Related Events (SREs) in Castration-Resistant Prostate Cancer (CRPC)

✍ G. Dranitsaris; S. Kaura 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB

Benefit of Adding Panitumumab to FOLFOX4

Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC): A Number-Needed-To-Treat (NNT) Analysis

✍ Douillard, J.Y.; Sienna, S.; Davison, C.; Braun, S.; Sidhu, R. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Survival benefit of definitive therapy i

Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis

✍ Gandaglia, Giorgio; Sun, Maxine; Trinh, Quoc-Dien; Becker, Andreas; Schiffmann, 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB